• Carlos A DiazGranados, Andrew J Dunning, Murray Kimmel, Daniel Kirby, John Treanor, Avi Collins, Richard Pollak, Janet Christoff, John Earl, Victoria Landolfi, Earl Martin, Sanjay Gurunathan, Richard Nathan, David P Greenberg, Nadia G Tornieporth, Michael D Decker, and H Keipp Talbot.
• From Sanofi Pasteur, Swiftwater (C.A.D., A.J.D., D.K., J.C., V.L., S.G., D.P.G., N.G.T., M.D.D.), ReSearch Pharmaceutical Services, Fort Washington (A.C.), and the Department of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh (D.P.G.) - all in Pennsylvania; Accelovance, Melbourne, FL (M.K.); University of Rochester, Rochester, NY (J.T.); Endeavor Clinical Trials, San Antonio (R.P.), and Martin Diagnostic Clinic, Tomball (E.M.) - both in Texas; PMG Research of Hickory, Hickory, NC (J.E.); Idaho Falls Infectious Diseases and Snake River Research, Idaho Falls, ID (R.N.); and the Department of Health Policy, Vanderbilt University School of Medicine (M.D.D.) and Vanderbilt University Medical Center (H.K.T.) - both in Nashville.
• N. Engl. J. Med.. 2014 Aug 14;371(7):635-45.

BackgroundAs compared with a standard-dose vaccine, a high-dose, trivalent, inactivated influenza vaccine (IIV3-HD) improves antibody responses to influenza among adults 65 years of age or older. This study evaluated whether IIV3-HD also improves protection against laboratory-confirmed influenza illness.MethodsWe conducted a phase IIIb-IV, multicenter, randomized, double-blind, active-controlled trial to compare IIV3-HD (60 μg of hemagglutinin per strain) with standard-dose trivalent, inactivated influenza vaccine (IIV3-SD [15 μg of hemagglutinin per strain]) in adults 65 years of age or older. Assessments of relative efficacy, effectiveness, safety (serious adverse events), and immunogenicity (hemagglutination-inhibition [HAI] titers) were performed during the 2011-2012 (year 1) and the 2012-2013 (year 2) northern-hemisphere influenza seasons.ResultsA total of 31,989 participants were enrolled from 126 research centers in the United States and Canada (15,991 were randomly assigned to receive IIV3-HD, and 15,998 to receive IIV3-SD). In the intention-to-treat analysis, 228 participants in the IIV3-HD group (1.4%) and 301 participants in the IIV3-SD group (1.9%) had laboratory-confirmed influenza caused by any viral type or subtype associated with a protocol-defined influenza-like illness (relative efficacy, 24.2%; 95% confidence interval [CI], 9.7 to 36.5). At least one serious adverse event during the safety surveillance period was reported by 1323 (8.3%) of the participants in the IIV3-HD group, as compared with 1442 (9.0%) of the participants in the IIV3-SD group (relative risk, 0.92; 95% CI, 0.85 to 0.99). After vaccination, HAI titers and seroprotection rates (the percentage of participants with HAI titers ≥ 1:40) were significantly higher in the IIV3-HD group. Conclusions: Among persons 65 years of age or older, IIV3-HD induced significantly higher antibody responses and provided better protection against laboratory-confirmed influenza illness than did IIV3-SD. (Funded by Sanofi Pasteur; ClinicalTrials.gov number, NCT01427309.).

24 keywords...

hide…